Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections.
We have studied the population dynamics in response to selective drug pressure of mixtures of wild-type and mutant HIV viruses exposed to either an inhibitor of the viral protease or a nonnucleoside allosteric inhibitor of the viral reverse transcriptase. In order to quantitate mutant virus present in a mixed population, we developed a selective plaque assay, which appears to be generally applicable to population dynamics studies where the viruses in question differ in the sensitivity to a given drug by at least 10-fold. In this assay system, the titer of virus in a mixture is measured in the absence and presence of a concentration of a specific inhibitor known to suppress virus replication by 99%. Virus detected in the presence of inhibitor corresponds to mutant virus, whereas detection in the absence of drug results in quantitation of the total virion population. Wild-type virus is then estimated by difference. Utilizing this system we studied the fate of mixtures of wild-type and the protease-resistant mutant variant I84V in the presence and absence of the cyclic urea HIV protease inhibitor, DMP 450. We also examined the dynamics of mixtures of wild-type and the resistant mutant variant, L100I, in the presence and absence of the drug DMP 266. In both systems we demonstrated that in the absence of drug, mutant virus is at a selective disadvantage for growth compared to wild-type, whereas in the presence of a specific inhibitor, mutant virus exhibits the selective growth advantage over wild-type virus. Better understanding of HIV population dynamics may allow the development of superior inhibitors and the careful application of combination therapy in the clinical setting.
Rayner
M M
MM
Molecular Biology Department, The DuPont Merck Pharmaceutical Company, Wilmington, Delaware 19880, USA.
Cordova
B
B
Jackson
D A
DA
D000480:Alkynes; D001381:Azepines / Q000494:pharmacology*; D048588:Benzoxazines; D003521:Cyclopropanes; D004352:Drug Resistance, Microbial; D006678:HIV / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D010078:Oxazines / Q000494:pharmacology*; D011157:Population Dynamics; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D013997:Time Factors; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology; D010948:Viral Plaque Assay
D000480:Alkynes; D001381:Azepines; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D014508:Urea; C098320:efavirenz; C099851:DMP 450